Time-Varying Proteinuria and Progression of IgA Nephropathy: A Cohort Study
Chen Tang,Pei Chen,Feng-Lei Si,Ji-Cheng Lv,Su-Fang Shi,Xu-Jie Zhou,Li-Jun Liu,Hong Zhang
DOI: https://doi.org/10.1053/j.ajkd.2023.12.016
IF: 11.072
2024-02-01
American Journal of Kidney Diseases
Abstract:RATIONALE & OBJECTIVE: <AbstractText Label="RATIONALE &amp; OBJECTIVE" NlmCategory="OBJECTIVE">Proteinuria is a surrogate end point for predicting long-term kidney outcomes in IgA nephropathy (IgAN) with levels&lt;1g/day identified as a therapeutic target. However, this threshold has not been sufficiently studied. We quantified the associations of progression of IgAN with various levels of proteinuria.</AbstractText>STUDY DESIGN: <AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">Observational cohort study.</AbstractText>SETTING & PARTICIPANTS: <AbstractText Label="SETTING &amp; PARTICIPANTS" NlmCategory="METHODS">1,530 patients with IgAN and at least 12 months of follow-up at Peking University First Hospital.</AbstractText>EXPOSURE: <AbstractText Label="EXPOSURE" NlmCategory="METHODS">Proteinuria levels updated over time (time-varying proteinuria, TVP).</AbstractText>OUTCOME: <AbstractText Label="OUTCOME" NlmCategory="RESULTS">A composite kidney outcome of a 50% reduction in the estimated glomerular filtration rate or end-stage kidney disease.</AbstractText>ANALYTICAL APPROACH: <AbstractText Label="ANALYTICAL APPROACH" NlmCategory="METHODS">Marginal structural models.</AbstractText>RESULTS: <AbstractText Label="RESULTS" NlmCategory="RESULTS">After a median follow-up period of 43.5 (IQR, 27.2-72.8) months, 254 patients (16.6%) developed the composite kidney outcome. A graded association was observed between TVP and composite kidney outcomes with higher risk among those with proteinuria of≥0.5g/day. Compared with TVP&lt;0.3g/day, the HRs for proteinuria levels of 0.3 to&lt;0.5g/day, 0.5 to&lt;1.0g/day, 1.0 to&lt;2.0g/day, and≥2.0g/day were 2.22 (95% CI, 0.88-5.58), 4.04 (95% CI, 1.93-8.46), 8.46 (95% CI, 3.80-18.83), and 38.00 (95% CI, 17.62-81.95), respectively. The trend was more pronounced in patients with baseline proteinuria of≥1.0g/day, among whom a higher risk was observed with TVP of 0.3 to&lt;0.5g/day compared with TVP&lt;0.3g/day (HR, 3.26 [95% CI, 1.07-9.92], P=0.04). However, in patients with baseline proteinuria levels of&lt;1g/day, the risk of composite kidney outcome only began to increase when TVP was≥1.0g/day (HR, 3.25 [95% CI, 1.06-9.90]).</AbstractText>LIMITATIONS: <AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Single-center observational study, selection bias, and unmeasured confounders.</AbstractText>CONCLUSIONS: <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study showed that patients with IgAN and proteinuria levels of&gt;0.5g/day, have an elevated risk of kidney failure especially among patients with proteinuria levels≥1.0g/day before initiating treatment. These data may serve to inform the selection of proteinuria targets in the treatment of IgAN.</AbstractText>PLAIN-LANGUAGE SUMMARY: <AbstractText Label="PLAIN-LANGUAGE SUMMARY" NlmCategory="UNASSIGNED">The presence of proteinuria has often been considered a surrogate end point and a possible therapeutic target in clinical trials in IgA nephropathy (IgAN). Some guidelines recommend a reduction in proteinuria to&lt;1g/day as a treatment goal based on the results of previous longitudinal studies. However, these findings may have been biased because they did not properly adjust for time-dependent confounders. Using marginal structural models to appropriately account for these confounding influences, we observed that patients with IgAN and proteinuria levels≥0.5g/day have an elevated risk of kidney failure, especially among patients who had proteinuria levels of≥1.0g/day before initiating treatment. These data may serve to inform the selection of proteinuria targets in the treatment of IgAN.</AbstractText>
urology & nephrology